Identifying antigen clusters for monitoring a global state of an immune system

• US 8,010,298 B2
• Filed: 01/22/2009
• Issued: 08/30/2011
• Est. Priority Date: 07/24/2000
• Status: Expired due to Term

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Cohen, Irun R., Hed, Guy, Getz, Gad, Domany, Eytan, Quintana, Francisco Javier
• Primary Examiner(s): Clow; Lori A
• Application Number:
  US12/357,449
• Publication Number:
  US 20090258790A1
• Time in Patent Office: 950 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/6803 General methods of protein analysis not limited to specific proteins or families of proteins
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 40/00 ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• CPC Class Codes: G16B 40/20 Supervised data analysis
• CPC Class Codes: G16B 40/30 Unsupervised data analysis

Abstract

Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.

Claims

1. A method of diagnosing Type I diabetes in a subject, the method comprising:

(a) determining an antibody pattern in a serum sample of said patient by assaying said serum sample for the presence of antibodies binding to antigens of a Type I diabetes disease classifier, said disease classifier comprising antigens of cluster 5 comprising Insulin and Aldolase, cluster 14 comprising Cartilage extract, cluster 26 comprising Histone II A, Lysine, Arginine, Laminin, Collagen X, Fibrinogen and Collagen VII, cluster 47 comprising Collagen X and Insulin and cluster 66 comprising Cardiolipin and Cartilage extract,

(b) comparing said antibody pattern to said classifier, wherein an antibody pattern including the presence of antibodies binding the antigens of said classifier indicates a diagnosis of Type I diabetes in the subject.

2. The method of claim 1, wherein determining said antibody pattern is effected by ELISA.

3. The method of claim 1, wherein said antibodies comprise IgG and/or IgM.

4. The method of claim 1, wherein said Type I diabetes disease classifier consists of antigens of cluster 5 comprising Insulin and Aldolase, cluster 14 comprising Cartilage extract, cluster 26 comprising Histone II A, Lysine, Arginine, Laminin, Collagen X, Fibrinogen and Collagen VII, cluster 47 comprising Collagen X and Insulin and cluster 66 comprising Cardiolipin and Cartilage.